Answers are grounded in this paper and cite their sources.
Review highlights key principles of pharmacovigilance to enhance safety in antituberculosis treatment, indicating the need for better monitoring systems.
Tuberculosis (TB) treatment requires prolonged multidrug therapy and is frequently complicated by adverse drug reactions (ADRs). Pharmacovigilance (PV) – the systematic detection, assessment, understanding, and prevention of medicine-related harm – is therefore central to TB control programs. Antituberculosis treatment, particularly for drug-resistant TB, is associated with hepatotoxicity, nephrotoxicity, severe cutaneous adverse reactions, cardiotoxicity, and clinically significant drug–drug interactions. Under-reporting of ADRs, diagnostic uncertainty, and limited integration of surveillance systems weaken patient-safety efforts in many settings. This review summarizes key principles of PV, regulatory frameworks, causality assessment tools, and surveillance methods relevant to TB care, and highlights real-world challenges and programmatic implications. Strengthening PV within national TB programs is essential to improve adherence, reduce preventable harm, and optimize treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Viswanathan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: